All In Biotech

Drug Trial Radar · NCT07714668

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

An Open-label , Multicenter, Multicohort, Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Aug 13, 2026

Primary completion

Apr 30, 2028

Study completion Aug 31, 2029

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

Conditions

  • Ovarian Cancer
  • Recurrent Ovarian Cancer

Interventions

  • SYS6041, bevacizumabDrug

    SYS6041: RP2D dose, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

  • SYS6041, carboplatin, bevacizumabDrug

    SYS6041: RP2D dose, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

  • paclitaxel, carboplatin, bevacizumabDrug

    Paclitaxel:175mg/m2, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

  • SYS6041, enlonstobart, bevacizumabDrug

    SYS6041: RP2D dose, ivgtt, Q3W Enlonstobart:360mg, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. AEs and SAEsTime frame: Baseline up to 30 days post last dose
  3. Recommended Phase 2 Dose (RP2D )Time frame: Up to approximately 3 years
  4. Objective Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.